Literature DB >> 26922535

Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.

Łukasz Bułdak1, Grzegorz Machnik2, Rafał Jakub Bułdak3, Krzysztof Łabuzek2, Aleksandra Bołdys2, Dariusz Belowski2, Marcin Basiak2, Bogusław Okopień2.   

Abstract

BACKGROUND: Incretin-based therapies in the treatment of type 2 diabetes mellitus are associated with significant improvements in glycemic control, which are accompanied by a beneficial impact on atherosclerosis. Macrophages are essential in the development of atherosclerotic plaques and may develop features that accelerate atherosclerosis (classically activated macrophages) or protect arterial walls against it (alternatively activated macrophages). Therefore, we explored whether beneficial actions of exenatide are connected with the influence on the macrophages' phenotype and synthesis of inflammatory and anti-inflammatory cytokines.
METHODS: Monocytes/macrophages were harvested from 10 healthy subjects. Cells were cultured in the presence of exenatide, exendin 9-39 (GLP-1 antagonist), LPS, IL-4, PKI (PKA inhibitor) and triciribine (PKB/Akt inhibitor). We measured the effects of the above-mentioned compounds on markers of macrophages' phenotype (inducible nitrous oxide (iNOS), arginase 1 (arg1) and mannose receptors) and concentration of nitrite, IL-1β, TNF-α and IL-10.
RESULTS: Exenatide significantly increased the level of IL-10 and decreased both TNF-α and IL-1β in LPS-treated monocytes/macrophages. Furthermore exenatide increased the expression of arg1-a marker of classical activation and reduced the LPS-induced expression of iNOS-a marker of classical activation. According to experiments with protein kinases inhibitors we found that proinflammatory markers were protein kinase A dependent, whereas the activation of alternative activation was similarly reliant on protein kinase A and B/Akt.
CONCLUSIONS: We showed that exenatide skewed the macrophages phenotype toward anti-inflammatory phenotype and this effect is predominantly attributable to protein kinase A and to a less extent to B/Akt activation.
Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Diabetes; Exenatide; Inflammation; Macrophage

Mesh:

Substances:

Year:  2015        PMID: 26922535     DOI: 10.1016/j.pharep.2015.10.008

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  14 in total

1.  Rationale for and Design of the Study of Early Enteral Dextrose in Sepsis: A Pilot Placebo-Controlled Randomized Clinical Trial.

Authors:  Faraaz Ali Shah; Georgios D Kitsios; Yingze Zhang; Alison Morris; Sachin Yende; David T Huang; Christopher P O'Donnell; Bryan J McVerry
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-05-30       Impact factor: 4.016

Review 2.  Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis.

Authors:  Faraaz Ali Shah; Hussain Mahmud; Teresa Gallego-Martin; Michael J Jurczak; Christopher P O'Donnell; Bryan J McVerry
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

3.  Analysis of N15-rat growth hormone after incubation with rat subcutaneous tissue and immune cells using ultra-pressure chromatography-mass spectrometry.

Authors:  Ninad Varkhede; Peters Björn-Hendrik; K Ryan Moulder; Philip Gao; Christian Schöneich; M Laird Forrest
Journal:  Anal Biochem       Date:  2021-10-20       Impact factor: 3.365

Review 4.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

5.  Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.

Authors:  Łukasz Bułdak; Grzegorz Machnik; Rafał Jakub Bułdak; Krzysztof Łabuzek; Aleksandra Bołdys; Bogusław Okopień
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-16       Impact factor: 3.000

6.  Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages.

Authors:  C Guo; T Huang; A Chen; X Chen; L Wang; F Shen; X Gu
Journal:  Braz J Med Biol Res       Date:  2016-11-21       Impact factor: 2.590

7.  Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.

Authors:  Lan He; Priscilla T Y Law; Chun Kwok Wong; Juliana C N Chan; Paul K S Chan
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

8.  Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats.

Authors:  Qian Zhang; Hongyue Yu; Xinhua Xiao; Ling Hu; Fengjiao Xin; Xiaobing Yu
Journal:  PeerJ       Date:  2018-03-01       Impact factor: 2.984

Review 9.  Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.

Authors:  Nicholas B Spath; Nicholas L Mills; Nicholas L Cruden
Journal:  Future Cardiol       Date:  2016-10-28

10.  Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.

Authors:  Valeria Garcia-Flores; Roberto Romero; Derek Miller; Yi Xu; Bogdan Done; Chharitha Veerapaneni; Yaozhu Leng; Marcia Arenas-Hernandez; Nabila Khan; Bogdan Panaitescu; Sonia S Hassan; Luis Marat Alvarez-Salas; Nardhy Gomez-Lopez
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.